Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European Urology Supplements  Volume 9, Issue 11, Pages 788-793 (December 2010) DOI: 10.1016/j.eursup.2010.10.004 Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 1 Cumulative incidence up to 10 yr in 875 men with locally advanced prostate cancer (PCa) treated with androgen-deprivation therapy (ADT) with or without radiation therapy (RT) of (A) PCa-specific mortality and (B) overall mortality. Reproduced with permission from Widmark et al [8]. European Urology Supplements 2010 9, 788-793DOI: (10.1016/j.eursup.2010.10.004) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 2 Overall survival at 10 yr in patients with locally advanced prostate cancer treated with radiation therapy plus short-term androgen-deprivation therapy (ADT) or long-term ADT [9]. CI=confidence interval; STADT=short-term androgen-deprivation therapy; LTADT=long-term androgen-deprivation therapy. European Urology Supplements 2010 9, 788-793DOI: (10.1016/j.eursup.2010.10.004) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 3 Mean scores for specific domains of the European Organisation for Research and Treatment of Cancer QLQ-C30 scale in patients with locally advanced prostate cancer randomised to treatment with short-term androgen-deprivation therapy (ADT) or long-term ADT following radiation therapy. Reproduced with permission from Bolla et al [9]. STADT=short-term androgen-deprivation therapy; LTADT=long-term androgen-deprivation therapy; Pre-tx=pretreatment. European Urology Supplements 2010 9, 788-793DOI: (10.1016/j.eursup.2010.10.004) Copyright © 2010 European Association of Urology Terms and Conditions